List of Oravig drug patents

Oravig is owned by Galt Pharms.

Oravig contains Miconazole.

Oravig has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Oravig are:

  • US7651698
  • US6916485
  • US8518442

Oravig was authorised for market use on 16 April, 2010.

Oravig is available in tablet;buccal dosage forms.

Oravig can be used as treatment of oropharyngeal candidiasis.

The generics of Oravig are possible to be released after 11 September, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7651698 GALT PHARMS Prolonged release bioadhesive therapeutic systems
Sep, 2022

(4 months ago)

US6916485 GALT PHARMS Prolonged release bioadhesive therapeutic systems
Sep, 2022

(4 months ago)

US8518442 GALT PHARMS Prolonged release bioadhesive therapeutic systems
Sep, 2022

(4 months ago)

Drugs and Companies using MICONAZOLE ingredient

Market Authorisation Date: 16 April, 2010

Treatment: Treatment of oropharyngeal candidiasis

Dosage: TABLET;BUCCAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in